Menu Content

Key research

Efficacy studies

Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine

A side by side, laboratory study, which compared the lung pathology (as a result of infection with Mycoplasma hyopneumoniae challenge) in pigs that had received a combination vaccine (1ml Ingelvac CircoFLEX® + 1ml Ingelvac MycoFLEX®) with those that received a 2ml, placebo injection (non-vaccinated, challenged controls, NVNC). A non-vaccinated, non-challenged, strict control group was also included in the study. All treatment groups were injected at 3 weeks of age with either 1ml of vaccine or 1ml of placebo. All pigs were challenged 33 days after vaccination with a virulent M hyo isolate (except the NVNC group). 28 days post-challenge all pigs in the study were sacrificed and had necropsies performed, using lung consolidation (average % lung consolidation score) as an indication of Mycoplasma hyopneumoniae pathology in each pig, and an average score calculated for each group.

Those pigs that had received the combination vaccine had a significantly lower average % lung consolidation score (3.9%) compared with the non-vaccinated, challenged group (14.3%). The strict controls (NVNC group) had an average score of 0%.

Ingelvac MycoFLEX® (as part of a combination with Ingelvac CircoFLEX®) provided a statistically significant reduction in lung pathology, in the face of a virulent M hyo challenge.

Eichmeyer M, Roof M, Piontkowski M, Hayes P, Saltzman R. Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine. Proc AASV 2009


Rapid Onset of Protection of Two Weeks for a Novel One Dose Mycoplasma Vaccine

A laboratory based, challenge model, comprising a side by side comparison of 3-4 week old piglets that received either Ingelvac MycoFLEX® or no vaccination. Both these groups were challenged with a virulent strain of Mycoplasma hyopneumoniae, two weeks after the day of vaccination. All pigs were euthanized and necropsies performed four weeks after the day of challenge. A third group (non-vaccinated and non-challenged) were included to act as strict negative controls. All pigs were assessed for lung pathology and median lesion scores calculated for each group.

The extent of lung lesions due to M hyo was significantly less in vaccinated pigs (median 0.123) compared to non-vaccinated, challenged pigs (median 2.925). None of the strict control group exhibited any lung lesions.

This study shows a rapid onset of immunity, of two weeks, following vaccination with Ingelvac MycoFLEX®.

Genzow M, von Freyburg M, Vyhmeister C. Rapid Onset of Protection of Two Weeks for a Novel One Dose Mycoplasma Vaccine. Proc Allen D Leman Swine Conf 2008


Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity against Mycoplasma hyopneumoniae

A laboratory challenge study including 4 groups of male cross-bred, commercial pigs aged approximately 3 weeks (day 0), all negative for M hyo and PRRS serum antibodies. Piglets in group 1 each received a vaccination with Ingelvac MycoFLEX® (1ml/pig), group 2 each received a vaccination with Ingelvac M hyo (2ml/pig) and group 3 each received a 1ml placebo (saline) on day 0. The 4th group received no treatment. Groups 1 to 3 were challenged (intra-tracheal) on day 184 (26 weeks) post vaccination with a heterologous strain of virulent Mycoplasma hyopneumoniae. All pigs were euthanized and necropsies performed, on day 217 (31 weeks), 33 days post challenge.

Significantly lower median % lung lesions were found in both vaccinated groups (6% and 7%) compared to the challenged, control group (13%). A reduced level of M hyo DNA was detected in the lung of pigs from both groups that had been vaccinated, compared to the non-vaccinated, challenged pigs. Also, a significantly higher secondary antibody response was noted in both vaccinated groups on day 14 post challenge and day 32 post challenge, compared to the non-vaccinated, challenged, control pigs.

A single dose of Ingelvac MycoFLEX® (1ml/pig) administered to pigs 3 weeks of age results in a duration of immunity against Mycoplasma hyopneumoniae, of at least 26 weeks.

Ohnesorge W, von Richthofen I. 26 weeks duration of immunity for Ingelvac MycoFLEX®. Proc APVS 2007


↑ Back to top